Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma — SYSTHER  

Pancreatic Tubular Adenocarcinoma Clinical Trial

Status Recruiting

Clinical Trial Summary

Interventional study of modulation of immune response in patients with pancreatic tubular adenocarcinoma after resection and gemcitabine treatment. When included, patients are pre-treated with moderate doses of cyclophosphamide. Then infusions of allogeneic mononuclear cells are given.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Tubular Adenocarcinoma

• NCT number: NCT01021800
• Study type: Interventional
• Source: Blood Transfusion Centre of Slovenia
• Contact: Borut Stabuc, MD PhD
• Phone: +38615222210
• Email: borut.stabuc@kclj.si
• Status: Recruiting
• Phase: Phase 2
• Start date: April 2009
• Completion date: December 2012